Efficacy and Safety of a 5-Day Regimen of Azacitidine for Patients with High-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Fujimaki, Katsumichi [1 ]
Miyashita, Kazuho [1 ]
Kawasaki, Rika [1 ]
Tomita, Naoto [2 ]
Ishigatsubo, Yoshiaki [2 ]
机构：
[1] Fujisawa City Hosp, Fujisawa, Kanagawa, Japan
[2] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa 232, Japan
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes
    Ettou, Sandrine
    Humbrecht, Catherine
    Benet, Blandine
    Kosmider, Olivier
    Droin, Nathalie
    Beyne-Rauzy, Odile
    Quesnel, Bruno
    Lacombe, Catherine
    Francois, Dreyfus
    Mayeux, Patrick
    Solary, Eric
    Fontenay, Michaela
    BLOOD, 2010, 116 (21) : 107 - 108
  • [42] COSTEFFECTIVENESS OF AZACITIDINE FOR THE TREATMENT OF IPSS INT-2 OR HIGH-RISK MYELODYSPLASTIC SYNDROMES IN THE UK
    Brereton, N.
    Murthy, A.
    Akehurst, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 131 - 131
  • [43] Cytogenetic responses to a 5-day dosing schedule of decitabine in patients (Pts) with myelodysplastic syndromes (MDS)
    Godley, L. A.
    Steensma, D. P.
    Baer, M. R.
    Slack, J. L.
    Buckstein, R.
    Larsen, J. S.
    Arora, S.
    Cullen, M. T.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] DECITABINE IN TREATMENT OF PATIENTS WITH INTERMEDIATEOR HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Kalinichenko, E.
    Ponteleeva, I.
    Fiodarava, A.
    Iskrov, I.
    Uss, A.
    LEUKEMIA RESEARCH, 2017, 55 : S71 - S72
  • [45] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
    Garcia-Manero, G.
    Gore, S. D.
    Kambhampati, S.
    Scott, B.
    Tefferi, A.
    Cogle, C. R.
    Edenfield, W. J.
    Hetzer, J.
    Kumar, K.
    Laille, E.
    Shi, T.
    MacBeth, K. J.
    Skikne, B.
    LEUKEMIA, 2016, 30 (04) : 889 - 896
  • [46] Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
    G Garcia-Manero
    S D Gore
    S Kambhampati
    B Scott
    A Tefferi
    C R Cogle
    W J Edenfield
    J Hetzer
    K Kumar
    E Laille
    T Shi
    K J MacBeth
    B Skikne
    Leukemia, 2016, 30 : 889 - 896
  • [47] Impact of Venetoclax on High-Risk Myelodysplastic Syndromes: A Retrospective Multicenter Analysis of Azacitidine-Venetoclax vs Azacitidine Monotherapy in Mexico
    Chacon-Rangel, Lyam Carlo
    Rodriguez-Rodriguez, Sergio
    Ontiveros-Austria, Juan Luis
    Demichelis-Gomez, Roberta
    Gomez-De Leon, Andres
    Rodriguez-Zuniga, Anna C.
    Inclan-Alarcon, Sergio Ignacio
    Corral-Herrera, Veronica Steffania
    Zapata-Canto, Nidia Paulina
    Apodaca-Chavez, Elia Ixel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S396 - S397
  • [48] Part 5: Myelodysplastic syndromes-Treatment of high-risk disease
    Meira Magalhaes, Silvia Maria
    Lopes Ferrari Chauffaille, Maria de Lourdes
    Rodrigues Pereira Velloso, Elvira Deolinda
    Buzzini, Renata
    Bernardo, Wanderley Marques
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (03) : 278 - 282
  • [49] EQUIVALENT EFFICACY OF AZACITIDINE FOR PATIENTS WITH POOR CYTOGENETICS AND HIGH RISK MYELODYSPLASTIC SYNDROME
    Kim, D. Y.
    Jang, M. J.
    Won, J. H.
    Kim, Y. K.
    Ahn, J. S.
    Bae, S. H.
    Shin, H. J.
    Kim, I.
    Ryoo, H. M.
    Lee, J. H.
    Choi, S. J.
    Mun, Y. C.
    Yoon, S. S.
    Oh, D.
    Lee, J. H.
    Lee, H. K.
    Lee, K. H.
    Kim, H. J.
    Park, S.
    Min, Y. H.
    Kim, B. K.
    Bang, S. M.
    Lee, J. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 279 - 280
  • [50] High-risk myelodysplastic syndromes in hypomethylants failure
    Gardin, Claude
    HEMATOLOGIE, 2010, 16 : 24 - 28
12345